First Turn Management LLC Cuts Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

First Turn Management LLC decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 18.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 114,247 shares of the company’s stock after selling 25,533 shares during the period. TransMedics Group makes up approximately 2.8% of First Turn Management LLC’s investment portfolio, making the stock its 12th largest position. First Turn Management LLC owned about 0.34% of TransMedics Group worth $17,937,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank grew its stake in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the last quarter. Pitcairn Co. lifted its holdings in shares of TransMedics Group by 1.5% during the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after buying an additional 78 shares in the last quarter. Harbour Capital Advisors LLC raised its stake in TransMedics Group by 1.7% during the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after acquiring an additional 81 shares in the last quarter. Signaturefd LLC lifted its stake in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the period. Finally, Arizona State Retirement System raised its position in TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

TMDX stock opened at $80.93 on Tuesday. The stock has a market capitalization of $2.72 billion, a PE ratio of 86.10 and a beta of 2.08. TransMedics Group, Inc. has a fifty-two week low of $66.76 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a 50 day moving average price of $125.63 and a 200 day moving average price of $139.55.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.12) EPS. Analysts forecast that TransMedics Group, Inc. will post 1.07 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Needham & Company LLC lowered their price objective on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. TD Cowen decreased their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday. Stephens raised their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group lowered their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $139.30.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.